Is your pharmacovigilance business continuity plan adapted to the current risk landscape?

According to the GVP guidelines, marketing authorisation holders (or their PV subcontractors) must establish a risk-based business continuity plan (BCP) covering all critical pharmacovigilance processes.

At PharmAdvice, we review our BCP annually.

But prompted by recent international events, we have given it a comprehensive re-evaluation to ensure it’s aligned with all relevant risks and threats.

With the improvements to our BCP, we have the operational resilience to sustain compliance and provide critical services to clients in the event of disasters and disruptions.

☝🏻 When did you last review your BCP or that of your PV subcontractor?